Arpeggio Bio

Arpeggio Bio develops drugs targeting transcription factors using AI…

Boulder, United States · Founded 2018 · $40.2M raised

Headquarters
Boulder, Colorado
Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$40.2M
Last Round
$20.0M Series BNov 2025
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

Summary

Arpeggio Bio is a Biotech company based in Boulder, United States, founded in 2018. It has raised $40.2M in total across 3 rounds, most recently a $20.0M Series B round in Nov 2025. Investors include Khosla Ventures, venBIO Partners and Builders VC.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BNov 2025
$20.0M

Sign up to see all 3 events

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
GRAILIPO

Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...

Menlo Park, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$2.1BJun 2026
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Ultima Genomics

Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...

Fremont, United States201–500Artificial Intelligence, Healthcare
Series ETotal funding$1.1BJun 2022
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Arpeggio Bio on Indexed.vc
<a href="https://indexed.vc/companies/arpeggio-biosciences"><img src="https://indexed.vc/api/badge/company/arpeggio-biosciences" alt="Arpeggio Bio on Indexed.vc" width="260" height="76" /></a>